Advaxis completes ADXS-HER2 pre-IND ending up in FDA Advaxis.

Inside our second pre-IND conference of the entire year, the FDA stayed collegial, receptive, and useful as we take the necessary steps to expand our oncology pipeline, stated Dr. John Rothman, EVP of Technology & Operations at Advaxis.. Advaxis completes ADXS-HER2 pre-IND ending up in FDA Advaxis, Inc., , a leader in developing the next era of immunotherapies for cancers and infectious illnesses, completed a pre-IND meeting with the FDA on November 22, 2011 to discuss the development arrange for ADXS-HER2, an immunotherapy for the treating HER2 expressing introduced new program compendiums on designer medication tests and toxicology of oral fluids. Also available can be an expanded GC/MS Designer Drug Library. The only resource of its kind, this searchable library includes developer stimulants that tend to be marketed as bath salts and also additional cannabinoid substances. In tandem with the launch of these new assets, Agilent is sponsoring regular webinars featuring industry experts who will discuss new LC/MS and MS applications for forensic recognition and analysis of developer drugs and metabolites.